Company Research Report: Leyden Labs
Company Overview
Name and Mission
- Company Name: Leyden Labs
- Mission: To free humanity from the burden of respiratory viruses, allowing people to live life to the fullest by stopping infections at the initial entry points, such as the nasal mucosa, using innovative nasal sprays.
Founding Details
- Founded by: Koenraad Wiedhaup (CEO), Jaap Goudsmit (Chief Scientist), and Ronald Brus (Chief Growth Officer).
- Founding Year: No information is available
Key People
- CEO: Koenraad Wiedhaup
- Chief Scientist: Jaap Goudsmit
- Chief Growth Officer: Ronald Brus
- Chief Medical Officer: Jintanat Ananworanich
- Chief Research Officer: Clarissa Koch
- Chief Financial Officer: Marieke van der Lans
- General Counsel: Xavier Maes
Headquarters
- Location: Leiden Laboratories B.V., Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands
- Leyden Labs Asia: 79 Science Park Drive, #04-05, Cintech IV, Singapore 118264
Other Details
- Number of Employees: No information is available
- Revenue: No information is available
- Company Known For: Developing intranasal antibodies to combat respiratory viruses by targeting the nasal mucosa for infections like COVID-19 and influenza.
Products
Product Offerings
- Nasal Sprays: Develops nasal sprays containing antibodies that protect against respiratory viruses.
High-Level Product Description
- PanFlu™: A lead candidate product aimed at providing broad protection against various influenza strains through an intranasal spray platform.
Key Features
- Antibody-Based: The sprays include antibodies that target the nasal mucosa.
- Broad Protection: Effective against multiple respiratory viral strains, including new and existing viruses.
- Universal Application: Designed to work irrespective of individual immune history or present comorbidities.
- Self-Administrable: Accessible and easy for users to administer themselves.
Recent Developments
Notable Events and Developments
- Funding: On January 9, 2025, Leyden Labs raised $70 million to further advance its intranasal antibody programs.
- Awards: PanFlu won the BioTech Breakthrough Award 2024 for “Monoclonal Antibody Solution of the Year.”
- Partnerships: Collaboration with technology and device companies to optimize intranasally-delivered antibodies.
New Product Launches and Features
- PanFlu™ Clinical Trials: Initiated Phase 1 clinical trials as announced on April 19, 2023.
- CR9114 Antibody: Exclusive licensing from Janssen to develop a pan-influenza antibody that is currently tested against avian flu and other influenza strains.
Appointments and Strategic Changes
- New CMO: Appointment of Jintanat Ananworanich as Chief Medical Officer on September 12, 2024.
- Investor Relations: Continued investor engagements with notable VCs like GV, Casdin Capital amongst others for the progression of their platforms and products.
Partnerships and Collaborations
- Collaboration with Academic and Commercial Entities: Leyden Labs works together with academics and commercial partners to enhance and develop their business and technological innovations.
This report is provided based on the data available and mentions "No information is available" for fields where data is not present.
